Jefferies Group's ABBV Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 99,673 shares of AbbVie Inc. (ABBV) worth $23.08 M, representing 0.11% of the portfolio. First purchased in 2017-Q1, this long-term strategic position has been held for 35 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in ABBV, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2024, adding 216,167 shares. Largest reduction occurred in Q4 2024, reducing 246,037 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's AbbVie (ABBV) Holding Value Over Time
Track share changes against reported price movement
Quarterly AbbVie (ABBV) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2017 | +8,008 | New Buy | 8,008 | $65.18 |
| Q2 2017 | -8,008 | Sold Out | 8,008 | $0.00 |
| Q4 2017 | +5,109 | New Buy | 5,109 | $96.69 |
| Q1 2018 | -5,109 | Sold Out | 5,109 | $0.00 |
| Q2 2018 | +32,529 | New Buy | 32,529 | $92.66 |
| Q3 2018 | +7,551 | Add 23.21% | 40,080 | $94.59 |
| Q4 2018 | +725 | Add 1.81% | 40,805 | $92.19 |
| Q1 2019 | -23,777 | Reduce 58.27% | 17,028 | $80.57 |
| Q2 2019 | -17,028 | Sold Out | 17,028 | $0.00 |
| Q4 2022 | +90,319 | New Buy | 90,319 | $161.61 |
| Q1 2023 | +66,801 | Add 73.96% | 157,120 | $159.37 |
| Q2 2023 | -136,480 | Reduce 86.86% | 20,640 | $134.73 |
| Q3 2023 | -1,078 | Reduce 5.22% | 19,562 | $149.06 |
| Q4 2023 | -19,562 | Sold Out | 19,562 | $0.00 |
| Q1 2024 | +63,554 | New Buy | 63,554 | $182.10 |
| Q2 2024 | +216,167 | Add 340.13% | 279,721 | $171.52 |
| Q3 2024 | +23,730 | Add 8.48% | 303,451 | $197.48 |
| Q4 2024 | -246,037 | Reduce 81.08% | 57,414 | $177.70 |
| Q1 2025 | +122,214 | Add 212.86% | 179,628 | $209.52 |
| Q2 2025 | -26,832 | Reduce 14.94% | 152,796 | $185.62 |
| Q3 2025 | -53,123 | Reduce 34.77% | 99,673 | $231.54 |
Jefferies Group's AbbVie Investment FAQs
Jefferies Group first purchased AbbVie Inc. (ABBV) in Q1 2017, acquiring 8,008 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held AbbVie Inc. (ABBV) for 35 quarters since Q1 2017.
Jefferies Group's largest addition to AbbVie Inc. (ABBV) was in Q2 2024, adding 279,721 shares worth $47.98 M.
According to the latest 13F filing for Q3 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 99,673 shares of AbbVie Inc. (ABBV), valued at approximately $23.08 M.
As of the Q3 2025 filing, AbbVie Inc. (ABBV) represents approximately 0.11% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in AbbVie Inc. (ABBV) was 303,451 shares, as reported at the end of Q3 2024.